X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs WOCKHARDT - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON WOCKHARDT BIOCON /
WOCKHARDT
 
P/E (TTM) x 38.1 -21.7 - View Chart
P/BV x 6.0 1.5 395.7% View Chart
Dividend Yield % 0.2 0.0 7,585.6%  

Financials

 BIOCON    WOCKHARDT
EQUITY SHARE DATA
    BIOCON
Mar-18
WOCKHARDT
Mar-18
BIOCON /
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1,1881,012 117.4%   
Low Rs305532 57.4%   
Sales per share (Unadj.) Rs68.7355.9 19.3%  
Earnings per share (Unadj.) Rs7.6-60.3 -12.5%  
Cash flow per share (Unadj.) Rs14.0-46.8 -29.9%  
Dividends per share (Unadj.) Rs1.000.01 10,000.0%  
Dividend yield (eoy) %0.10 10,338.2%  
Book value per share (Unadj.) Rs86.3257.8 33.5%  
Shares outstanding (eoy) m600.00110.63 542.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.2 500.9%   
Avg P/E ratio x98.9-12.8 -772.1%  
P/CF ratio (eoy) x53.4-16.5 -323.8%  
Price / Book Value ratio x8.63.0 288.8%  
Dividend payout %13.20 -79,820.1%   
Avg Mkt Cap Rs m447,90085,379 524.6%   
No. of employees `0006.16.3 98.3%   
Total wages/salary Rs m9,3119,371 99.4%   
Avg. sales/employee Rs Th6,705.86,295.0 106.5%   
Avg. wages/employee Rs Th1,514.21,498.3 101.1%   
Avg. net profit/employee Rs Th736.9-1,066.3 -69.1%   
INCOME DATA
Net Sales Rs m41,23439,369 104.7%  
Other income Rs m2,0621,202 171.5%   
Total revenues Rs m43,29640,571 106.7%   
Gross profit Rs m8,29118 45,306.0%  
Depreciation Rs m3,8511,495 257.5%   
Interest Rs m6152,555 24.1%   
Profit before tax Rs m5,887-2,830 -208.1%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,569257 610.5%   
Profit after tax Rs m4,531-6,669 -67.9%  
Gross profit margin %20.10 43,256.8%  
Effective tax rate %26.7-9.1 -293.4%   
Net profit margin %11.0-16.9 -64.9%  
BALANCE SHEET DATA
Current assets Rs m41,48633,796 122.8%   
Current liabilities Rs m21,41326,917 79.6%   
Net working cap to sales %48.717.5 278.6%  
Current ratio x1.91.3 154.3%  
Inventory Days Days6479 80.6%  
Debtors Days Days9489 105.5%  
Net fixed assets Rs m50,66139,664 127.7%   
Share capital Rs m3,000553 542.3%   
"Free" reserves Rs m48,80827,968 174.5%   
Net worth Rs m51,80828,522 181.6%   
Long term debt Rs m17,89821,731 82.4%   
Total assets Rs m99,89781,620 122.4%  
Interest coverage x10.6-0.1 -9,833.0%   
Debt to equity ratio x0.30.8 45.3%  
Sales to assets ratio x0.40.5 85.6%   
Return on assets %5.2-5.0 -102.2%  
Return on equity %8.7-23.4 -37.4%  
Return on capital %9.6-7.7 -125.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,0589,807 123.0%   
Fx outflow Rs m7,3481,789 410.8%   
Net fx Rs m4,7108,019 58.7%   
CASH FLOW
From Operations Rs m6,621684 967.4%  
From Investments Rs m-6,8406,302 -108.5%  
From Financial Activity Rs m-2,397-7,695 31.2%  
Net Cashflow Rs m-2,612-664 393.4%  

Share Holding

Indian Promoters % 40.4 74.5 54.2%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 2.3 365.2%  
FIIs % 10.7 7.7 139.0%  
ADR/GDR % 0.0 0.1 -  
Free float % 19.9 15.4 129.2%  
Shareholders   109,995 67,757 162.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 140 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets ended their day on a positive note today ahead of counting of Lok Sabha Election 2019 to be done tomorrow.

Related Views on News

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 22, 2019 (Close)

TRACK BIOCON

BIOCON - STERLING BIOTECH COMPARISON

COMPARE BIOCON WITH

MARKET STATS